Navigation Links
Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
Date:12/11/2008

available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the results of the company's Vaxfectin(R)-formulated H5N1 influenza DNA vaccine Phase 1 clinical trial and the results of nonclinical mouse studies of Vaxfectin(R)-formulated influenza vaccines produced by the company's RapidResponse(TM) manufacturing system. Risks and uncertainties include whether Vical or others will continue development of the H5N1 pandemic influenza vaccines or the RapidResponse(TM) DNA vaccine platform; whether H5N1 influenza DNA vaccine Phase 1 clinical trial results will be confirmed in larger studies; whether nonclinical results from mouse studies will advance to human clinical testing, and if so, whether such testing will yield similar results; whether the company will receive all of the NIH grant funding; whether DNA vaccines against H5N1 influenza or any other targets will be successfully developed and commercialized; whether Vical or its collaborative partners will seek or gain approval to market the influenza vaccine or any other product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; whether Vical or others will secure funding to advance the pandemic influenza DNA vaccine program; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update th
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
2. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
5. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
6. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
7. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
11. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/4/2015)... Ltd. (NASDAQ: ELOS ), a leading global aesthetic device ... ended June 30, 2015. Second Quarter ... , Revenue of $73.5 million, up 14% year-over-year, or ... grew 45% year-over-year. , International sales grew 8% year-over-year, ... the EMEA region and 25% product growth in the Asia-Pacific ...
(Date:8/3/2015)... 4, 2015   The Intellectual Property and ... leading provider of intelligent information for businesses and ... CMR Pharmaceutical R&D Factbook , the biopharmaceutical industry,s ... around declines in R&D, the analysis identifies a ... milestone and forecasts sales to reach $1.3 trillion ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Pharma Sales to Grow Beyond $1 Trillion 2
... HAMBURG , Feb. 3 , The International ... a global teleconference that will: , Detail the launch of ... its symposium in Hamburg being held February 5-6, ... develop a comprehensive, evidence-based consensus on the use of NPWT; ...
... BALTIMORE , Feb. 2 Celsis In Vitro, Inc. ... lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical ... District of Illinois in Chicago .  XenoTech and ... that certain processes and methods performed by XenoTech associated with its ...
Cached Medicine Technology:The International Negative Pressure Wound Therapy Expert Panel to Announce Results of Inaugural Symposium in Hamburg 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
(Date:8/4/2015)... ... August 04, 2015 , ... One of the nation’s leading experts in ... book, The Pain Antidote , which provides strategies for people who suffer from ... Chronic Pain Treatment Program, wrote the book in conjunction with Katherine Ketcham, an author ...
(Date:8/4/2015)... ... 2015 , ... Buckeye Health Plan is reminding parents to ... covered for members under the Healthchek program . , “Many schools have ... immunizations may not be allowed to attend when school begins in August,” said ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... with full examination now offered by the world renowned Beverly Hills facelift ... facial appearance through cosmetic surgery techniques helps individuals to achieve an outer appearance ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics heaven,” “mecca ... experience inside Naimie’s Beauty Center in LA. Now MENAJI is part of that experience ... , Naimie’s Beauty Center has been a favorite of makeup artists and hair pros ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
Breaking Medicine News(10 mins):Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2
... and Hollywood elite celebrated the launch of the ... Biomedical Skin Treatments - ... Fisher and beauty industry veteran Paul Scott Premo ... the heart of Los Angeles. (Photo: ...
... but some risks tied to dose strength, study says ... improves walking ability in some people with multiple sclerosis. , ... 18 to 70, the participants were randomly assigned to receive ... day for 14 weeks. The patients, walking speed was assessed ...
... 27 /PRNewswire-Asia/ -- Winner Medical Group Inc.,(OTC ... a leading,manufacturer in the Chinese medical dressing ... that the European Patent Office has decided ... to Winner Medical. The,following are specifically covered ...
... (Nasdaq: ENDP ) announced today that it ... and market the investigational drug axomadol in the United ... entity discovered by Grunenthal and currently in Phase II ... chronic pain and diabetic peripheral neuropathic pain.Under the license ...
... to drive solid cash net income growthHAMILTON, Bermuda, Feb. 27 ... announced its results for the quarter and year ended December ... 2008 totaled $242.5 million, an increase of 6.5%, over the ... 2008 totaled $938.1 million, an increase of 4.3%, over the ...
... 27 Fourth quarter of 2008 as compared to ... UHT ) announced today that for the quarter ... or $.07 per diluted share, as compared to reported net ... the comparable quarter in the prior year. Included in net ...
Cached Medicine News:Health News:Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo 2Health News:Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo 3Health News:Drug Improves Mobility in Some MS Patients 2Health News:Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method 2Health News:Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method 3Health News:Endo Licenses Novel Pain Therapy from Grunenthal 2Health News:Endo Licenses Novel Pain Therapy from Grunenthal 3Health News:Endo Licenses Novel Pain Therapy from Grunenthal 4Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 2Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 3Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 4Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 5Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 6Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 7Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 8Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 9Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 10Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 11Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 12Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 13Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 14Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 15Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 16Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 17Health News:Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008 18Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 11
... variety of colors and classic shapes, ... designed with elegant jewel detail. With ... that are made from the same ... our fine timepieces, Timex branded frames ...
... captures the whimsy, charm and cutting edge ... design is inspired by Cynthia Rowley's creativity, ... from the Kenmark Group and B Robinson ... features eight optical and four sunwear designs ...
... collection offers a broad and definitive line ... value-minded consumer. The core line is a ... age and price sensitivity. The common theme ... high quality craftsmanship and a competitive price-versus-value ...
... The new Eyewear ... lifestyle proposition, encompassing elegance, ... well as a dedication ... Mirroring key attributes of ...
Medicine Products: